PROPANC BIOPHARMA, INC. Retained Earnings
PROPANC BIOPHARMA, INC. (PPCB) had Retained Earnings of -$140.84 million as of 2026-03-31, per its S-1 filed 2026-07-17.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-07-17
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$140.84M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$134.48M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$130.46M.
- 2025-06-30: Retained Earnings (Accumulated Deficit) -$125.62M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-03-31 | -$140.84M S-1 · filed 2026-07-17 | |
| 2025-12-31 | -$134.48M S-1 · filed 2026-04-10 | |
| 2025-09-30 | -$130.46M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | -$125.62M S-1 · filed 2026-07-17 | |
| 2025-03-31 | -$121.55M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | -$67.48M 10-Q · filed 2025-02-14 | |
| 2024-09-30 | -$67.05M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | -$66.70M S-1 · filed 2026-07-17 | |
| 2024-03-31 | -$66.34M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | -$65.80M 10-Q · filed 2024-02-20 | |
| 2023-09-30 | -$65.18M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | -$64.68M 10-K · filed 2024-09-30 | |
| 2023-03-31 | -$63.88M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | -$63.07M 10-Q · filed 2023-02-10 | |
| 2022-09-30 | -$62.56M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | -$61.56M 10-K · filed 2023-09-28 | |
| 2022-03-31 | -$60.40M 10-Q · filed 2022-05-16 | |
| 2021-12-31 | -$59.70M 10-Q · filed 2022-02-14 | |
| 2021-09-30 | -$58.80M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | -$58.20M 10-K · filed 2022-09-28 | |
| 2021-03-31 | -$57.03M 10-Q · filed 2021-05-14 | |
| 2020-12-31 | -$56.61M 10-Q · filed 2021-02-12 | |
| 2020-09-30 | -$56.21M 10-Q · filed 2020-11-16 | |
| 2020-06-30 | -$55.78M 10-K · filed 2021-09-28 | |
| 2020-03-31 | -$56.99M 10-Q · filed 2020-05-15 | |
| 2019-12-31 | -$54.40M 10-Q · filed 2020-02-14 | |
| 2019-09-30 | -$52.53M 10-Q · filed 2019-11-14 | |
| 2019-06-30 | -$51.04M 10-K · filed 2020-10-01 | |
| 2019-03-31 | -$49.44M 10-Q · filed 2019-05-15 | |
| 2018-12-31 | -$48.86M 10-Q · filed 2019-02-14 | |
| 2018-09-30 | -$47.41M 10-Q · filed 2018-11-13 | |
| 2018-06-30 | -$45.28M 10-K · filed 2019-10-15 | |
| 2018-03-31 | -$43.86M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | -$42.37M 10-Q · filed 2018-02-09 | |
| 2017-09-30 | -$40.17M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | -$38.24M 10-K · filed 2018-09-17 | |
| 2017-03-31 | -$36.61M 10-Q · filed 2017-05-08 | |
| 2016-12-31 | -$35.24M 10-Q · filed 2017-02-14 | |
| 2016-09-30 | -$31.48M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | -$30.38M 10-K · filed 2017-09-28 | |
| 2016-03-31 | -$27.52M 10-Q · filed 2016-05-16 | |
| 2015-12-31 | -$25.37M 10-Q · filed 2016-02-16 | |
| 2015-09-30 | -$21.80M 10-Q · filed 2015-11-16 | |
| 2015-06-30 | -$20.97M 10-K · filed 2016-09-28 | |
| 2015-03-31 | -$19.14M 10-Q · filed 2015-05-15 | |
| 2014-12-31 | $18.68M 10-Q · filed 2015-02-17 | |
| 2014-09-30 | $18.34M 10-Q · filed 2014-11-19 | |
| 2014-06-30 | -$17.55M 10-K · filed 2015-09-30 | $17.55M 10-K · filed 2014-10-14 |
| 2012-09-30 | $15.77M 10-Q · filed 2012-11-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |